Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of tildrakizumab in active psoriatic arthritis
2016-003937-62Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Tildrakizumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Started Jan 2017; status: completed.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2016-003937-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003937-62.